Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1156-1166

  Hwang, Hyeon Seok ^a   Yang, Keum Jin ^b   Park, Ki Cheol ^b   Choi, Hyun Soo ^b   Kim, So Hee ^b   Hong, Sung Youp ^a   Jeon, Byeong Hwa ^c   Chang, Yoon Kyung ^a   Park, Cheol Whee ^a   Kim, Suk Young ^a   Lee, Sang Ju ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

cyclooxygenase 2; inflammation; ischemia reperfusion; paricalcitol; prostaglandin E2

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALCIUM; CELECOXIB; CREATININE; CYCLOOXYGENASE 2; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; PARICALCITOL; PHOSPHATE; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; RANTES; UREA; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALCIUM BLOOD LEVEL; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEMATOCRIT; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE NECROSIS; MACROPHAGE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NEPHRITIS; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; UPREGULATION; UREA NITROGEN BLOOD LEVEL;

CYCLOOXYGENASE-2; INFLAMMATION; ISCHEMIA REPERFUSION; PARICALCITOL; PROSTAGLANDIN E2;

ANIMALS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; ERGOCALCIFEROLS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCITRIOL; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84877970277     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs540     Document Type: Article

References (39)

1. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485
2. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130: 41-50
3. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665
4. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol 2008; 109: e102-e107
5. Rabb H. The T cell as a bridge between innate and adaptive immune systems: implications for the kidney. Kidney Int 2002; 61: 1935-1946
6. Bajwa A, Kinsey GR, Okusa MD. Immune mechanisms and novel pharmacological therapies of acute kidney injury. Curr Drug Targets 2009; 10:1196-1204
7. Drüeke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens 2005; 14: 343-349
8. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int 2011; 79:702-707
9. Seibert E, Levin NW, Kuhlmann MK. Immunomodulating effects of vitamin D analogs in hemodialysis patients. Hemodial Int 2005; 9(Suppl 1):S25-S29
10. van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvi-tamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101
11. Park JW, Bae EH, Kim IJ et al. Paricalcitol attenuates cyclospor-ine-induced kidney injury in rats. Kidney Int 2010; 77: 1076-1085
12. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008; 19: 1741-1752
13. Park JW, Bae EH, Kim IJ et al. Renoprotective effects of paricalci-tol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol 2010; 298: F301-F313
14. Patel NS, Cuzzocrea S, Collino M et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 2007; 562:148-154
15. Feitoza CQ, Câmara NO, Pinheiro HS et al. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. Int Immunopharmacol 2005; 5: 79-84
16. Feitoza CQ, Semedo P, Gonçalves GM et al. Modulation of inflammatory response by selective inhibition of cyclooxygenase-1 and cyclooxygenase-2 in acute kidney injury. Inflamm Res 2010; 59: 167-175
17. Hao CM, Breyer MD. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 2007; 71:1105-1115
18. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51: 311-336
19. Moreno J, Krishnan AV, Swami S et al. Regulation of prostaglan-din metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65: 7917-7925
20. Hamada T, Tsuchihashi S, Avanesyan A et al. Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutro-phil recruitment in hepatic ischemia/reperfusion injury. J Immunol 2008; 180: 1843-1853
21. Daemen MA, de Vries B, Buurman WA. Apoptosis and inflammation in renal reperfusion injury. Transplantation 2002; 73: 1693-1700
22. Saikumar P, Venkatachalam MA. Role of apoptosis in hypoxic/ischemic damage in the kidney. Semin Nephrol 2003; 23: 511-521
23. Park JW, Cho JW, Joo SY et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012; 683: 301-309
24. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393
25. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6: 652-658
26. Li L, Okusa MD. Macrophages, dendritic cells, and kidney ische-mia-reperfusion injury. Semin Nephrol 2010; 30: 268-277
27. Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007; 3: 164-170
28. Donnahoo KK, Shames BD, Harken AH et al. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999; 162: 196-203
29. Vaddi K, Newton RC. Comparison of biological responses of human monocytes and THP-1 cells to chemokines of the inter-crine-beta family. J Leukoc Biol 1994; 55: 756-762
30. Rice JC, Spence JS, Megyesi J et al. Expression of the polymeric immunoglobulin receptor and excretion of secretory IgA in the postischemic kidney. Am J Physiol 1999; 276: F666-F673
31. van Kooten C, Woltman AM, Daha MR. Immunological function of tubular epithelial cells: the functional implications of CD40 expression. Exp Nephrol 2000; 8: 203-207
32. van Kooten C, Gerritsma JS, Paape ME et al. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997; 51: 711-721
33. Suzuki J, Ogawa M, Watanabe R et al. Roles of prostaglandin E2 in cardiovascular diseases. Int Heart J 2011; 52: 266-269
34. Takahashi T, Zhu SJ, Sumino H et al. Inhibition of cyclooxygen-ase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 2005; 78: 195-204
35. Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003; 278: 12151-12156
36. Aoudjit L, Potapov A, Takano T. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. Am J Physiol Renal Physiol 2006; 290: F1534-F1542
37. Vukicevic S, Simic P, Borovecki F et al. Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure. Kidney Int 2006; 70: 1099-1106
38. Kanekura T, Laulederkind SJ, Kirtikara K et al. Cholecalciferol induces prostaglandin E2 biosynthesis and transglutaminase activity in human keratinocytes. J Invest Dermatol 1998; 111: 634-639
39. Kim YO, Li C, Sun BK et al. Preconditioning with 1, 25-dihydrox-yvitamin D3 protects against subsequent ischemia-reperfusion injury in the rat kidney. Nephron Exp Nephrol 2005; 100: e85-e94